ATCC has been awarded a contract by the National Cancer Institute to develop a technology infrastructure to support the production, intake and distribution of cancer cell lines for the international research community.
The company said Wednesday it will build the infrastructure for the Human Cancer Models Initiative that aims to generate as many as 1,000 new cancer cell models.
HCMI is a collaborative effort of NCI, Cancer Research UK, the Wellcome Trust Sanger Institute and Hubrecht Organoid Technology.
“ATCC has been supporting cancer research for more than 50 years,” said Mindy Goldsborough, chief science and technology officer of ATCC.
“These new models could transform how we study cancer, including how the disease progresses and develops drug resistance, and help guide the development of new cancer therapies for the millions living with and affected by cancer worldwide,” Goldsborough added.
NCI and its partners aim to produce models using tumor tissues of multiple patients diagnosed with different types of cancer.
The project also seeks to provide researchers access to data from genetic analysis of the models and anonymized clinical data on patients as well as their tumors and response to treatments.